Current NDC auxiliary source row compounder:3433

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 79559-4104
Product Ndc: 79559-4104
Product Ndc Digits: 795594104
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: S-TA104
Proprietary Name Suffix: [empty]
Nonproprietary Name: S-TA104
Dosage Form Name: PELLET, IMPLANTABLE
Route Name: SUBCUTANEOUS
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: F. H. Investments. Inc. DBA Asteria Health
Establishment Name: F. H. Investments. Inc. DBA Asteria Health
Establishment Fei: [empty]
Substance Name: TESTOSTERONE; ANASTROZOLE
Active Ingredients Info: 100 mg/104 mg; 4 mg/104 mg
History Active Ingredients Raw: TESTOSTERONE; ANASTROZOLE
History Active Ingredients Info Raw: 100 mg/104 mg; 4 mg/104 mg
History Dosage Raw: PELLET, IMPLANTABLE
Dea Schedule: CIII
Package Ndc Raw: 79559-4104-1
Package Ndc: 79559-4104-1
Package Ndc Digits: 7955941041
Package Ndc11: 79559410401
Package Description: 104 mg in 1 VIAL, PLASTIC (79559-4104-1)
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:3433
Source Row Number: 3433
Source Row Hash: 1eb6fa27e03fcb144f416b8351a408e9d04efa7398ef54c3a8bbb9cb9d3b1883
Import Run Id: 20261025T224840Z
Loaded At: 2026-10-25 22:53:27

Exact raw FDA source fields#

{
    "ROUTENAME": "SUBCUTANEOUS",
    "PRODUCTNDC": "79559-4104",
    "DEASCHEDULE": "CIII",
    "LABELERNAME": "F. H. Investments. Inc. DBA Asteria Health",
    "SUBSTANCENAME": "TESTOSTERONE; ANASTROZOLE",
    "DOSAGEFORMNAME": "PELLET, IMPLANTABLE",
    "NDCPACKAGECODE": "79559-4104-1",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "S-TA104",
    "REPORTINGPERIOD": "2025-2",
    "NONPROPRIETARYNAME": "S-TA104",
    "PACKAGEDESCRIPTION": "104 mg in 1 VIAL, PLASTIC (79559-4104-1) ",
    "ACTIVEINGREDIENTSINFO": "100 mg/104 mg; 4 mg/104 mg",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:3433
Source Row Number: 3433
Status Scope: package
Lookup Ndc: 79559-4104-1
Lookup Ndc Digits: 7955941041
Product Ndc: 79559-4104
Product Ndc Digits: 795594104
Package Ndc: 79559-4104-1
Package Ndc Digits: 7955941041
Package Ndc11: 79559410401
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2025-2
Reporting Period: 2025-2
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 1eb6fa27e03fcb144f416b8351a408e9d04efa7398ef54c3a8bbb9cb9d3b1883
Import Run Id: 20261025T224840Z
Loaded At: 2026-10-25 22:53:27